The Tug McGraw Foundation helped advance discussion about the importance of QOL research for brain tumor patients and their families.
- 28 multi-disciplinary cancer researchers, clinicians and advocates participated in the day and half session
- Solution-focused discussion to
- Identify barriers to producing good QOL research
- Develop and prioritize strategies for overcoming those barriers
- Dr. Anna Barker, Deputy Director, NCI, presented "How NCI is Shaping Quality of Life for Brain Tumor Patients Through Science and Technology"
- The "clarity and content of the agenda was excellent" according to participants
- Recognition from all involved that TMF has the presence to influence thinking and achieve tangible, relevant outcomes
This meeting was supported in part by MGI Pharma, a wholly-owned subsidiary of Eisai Corporation of North America
"This was the meeting that had to happen,"
Brian Patrick O’Neill,
"... You and your team managed to pull together an incredibly diverse group of people who - in the end - really seemed to coalesce around some very important issues ... If you had told me on the bus Monday night that such a consensus would be reached by noon on Tuesday, I would have laughed..."
Henry M. Jackson Foundation for the Advancement of Military Medicine
"It was truly a great experience, and I am honored to serve in whatever capacity you like."
Christina A. Meyers,
Ph.D., ABPP, MD Anderson Cancer Center